Responses

PDF
Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Hepatitis C elimination by 2030 is feasible in developed countries but challenging in resource poor developing countries
    Sir,

    The World Health Organisation's setting of global viral hepatitis elimination targets, focused on hepatitis B & C, is most welcome1. In their commentary article, Hellard, Sacks-Davis & Doyle describe strategies by which hepatitis C elimination by 2030 can be achieved by a combination of direct acting antiviral drugs against hepatitis C, opioid substitution therapy and needle and syringe programmes...

    Show More
    Conflict of Interest:
    None declared.